Semi-mechanistic Model of ATG-101, a PD-L1/4-1BB Bispecific Antibody, for Treatment of Solid Tumors Poster ATG-101,一种针对 PD-L1/4-1BB 的双特异性抗体,用于实体瘤治疗的半机制模型 Abstract Trimer formation is key to the pharmacology of the bispecific ATG-101 but is difficult…Renee Fisher2024 年 9 月 16 日
Blinatumomab Trimer Formation Poster 布林妥莫单抗(Blinatumomab)三聚体形成 Insights from a Mechanistic PKPD Model on the Implications for Switching from Infusion to Subcutaneous…Renee Fisher2024 年 9 月 16 日
Dose Selection for DuoBody®-PD-L1x4-1BB (GEN1046) Poster DuoBody®-PD-L1x4-1BB (GEN1046) 的剂量选择 Abstract DuoBody®-PD-L1x4-1BB (GEN1046) is an investigational, first-in-class, bispecific antibody designed to elicit an antitumor immune…Renee Fisher2024 年 9 月 9 日
Optimizing Avidity of Bispecific Drugs Poster 优化双特异性药物的活性 Abstract Bispecific drugs have great potential to improve tissue selectivity through avid binding interactions but…Renee Fisher2024 年 9 月 9 日
Effects of Tissue Targeting Bispecifics on Therapeutic Window Poster 组织靶向双特异性药物对治疗窗口的影响 Abstract Objectives: The presence of target receptors in non-target tissues can reduce the therapeutic window…Renee Fisher2024 年 9 月 9 日
Optimizing Clinical Development: Saving Time and Costs Case Study 优化临床开发:节约时间和成本 战略机械建模解决方案可帮助免疫肿瘤生物技术加速其新型疗法的临床开发。Danielle Pillsbury2024 年 8 月 16 日